Please login to order a test.
- ABL1 Mutation Analysis for Resistance to Imatinib Mesylate
- Gleevec Resistance Mutation Analysis
- Imatinib Mesylate Resistance Analysis
Mutations within the BCR-ABL1 kinase domain in imatinib-treated chronic myeloid leukemia are the main mechanism of acquired resistance. The early detection of mutations should provide clinical benefit by allowing early intervention. Candidates for the BCR-ABL1 kinase domain mutation analysis include:
• Patients who fail to respond to imatinib therapy
• Patients with significant increase in BCR-ABL1 levels as detected by the quantitative BCR-ABL1 assay
• Patients with a loss of cytogenetic or hematologic response
• Patients in accelerated phase/blast crisis
In vitro studies indicate that this analysis has a mutation detection sensitivity of ∼20%. Mutations occurring outside of the analyzed region of the ABL kinase domain will also not be detected by this assay.
Polymerase chain reaction (PCR); direct sequencing; capillary electrophoresis
Whole blood or bone marrow
3 to 5 mL whole blood or 1 to 2 mL bone marrow
2 mL whole blood or 1 mL bone marrow
Submit at room temperature. Specimens should arrive in the laboratory within 48 hours of collection. Indicate date and time of collection on request form.
Causes for Rejection
Please direct any questions regarding this test to oncology customer service at 800-345-4363.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|480510||BCR-ABL1 kinase domain||480511||Result:||55135-8|
|480510||BCR-ABL1 kinase domain||480512||Nucleotide Change:||48004-6|
|480510||BCR-ABL1 kinase domain||480513||Predicted Amino Acid Change:||48005-3|
|480510||BCR-ABL1 kinase domain||480843||Interpretation:||50398-7|
|480510||BCR-ABL1 kinase domain||480844||Methodology:||49549-9|
|480510||BCR-ABL1 kinase domain||480515||Director Review:||72486-4|
|480510||BCR-ABL1 kinase domain||480846||BCR-ABL1 kinase domain||N/A|